A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers ...

Increased dietary folic acid intake may lead to adverse health effects, including inflammation and neurotoxicity, ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors, with symptoms varying widely in severity ...

UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. The U.S. Food and Drug Administration granted full approval to Elahere in ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate ...

Genmab (GMAB) announced updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that ...